{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T01:36:45Z","timestamp":1762911405530,"version":"3.45.0"},"reference-count":37,"publisher":"Oxford University Press (OUP)","issue":"11","license":[{"start":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T00:00:00Z","timestamp":1759708800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100017655","name":"Incyte Corporation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100017655","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,11,11]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>In the current Canadian treatment landscape for relapsed or refractory diffuse large B-cell lymphoma (R\/R DLBCL), eligibility for autologous stem cell transplantation (ASCT) guides the choice of salvage treatment. CD19 chimeric antigen receptor T-cell (CAR-T) therapies have improved outcomes in patients with chemorefractory DLBCL, but access is limited to eligible patients. This subanalysis of the RE-MIND2 observational retrospective cohort study investigated treatment patterns for R\/R DLBCL in Canada.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Patients and methods<\/jats:title>\n                    <jats:p>Data from patients enrolled in RE-MIND2 treated between 2010 and 2020 at 2 Canadian centers were retrospectively collected from health records. Descriptive statistics were used to analyze baseline characteristics, treatment initiated, and duration of treatment by line of therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>One hundred and nine patients were included; 74.2% of patients were eligible for ASCT as 2L therapy, and 45.4% received transplants. ASCT eligibility for third- (3L) and fourth-line (4L) therapy declined to 17.1% and 5.9%, respectively. Patients received a wide variety of treatments in 3 and 4L. CAR-T therapy became available in 3 and 4L by the end of 2019. Median durations of treatment were &amp;lt;2.6 months in all lines of therapy; median time to next treatment ranged from 3.4 months in 4L to 5.3 months in 2L.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Results of our study support that ASCT-ineligible patients have a poor prognosis with conventional salvage chemotherapy. Before the availability of novel immunotherapies, no apparent standard of care was observed for Canadian patients with R\/R DLBCL who were ineligible for or did not receive ASCT, especially after 2L treatment.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1093\/oncolo\/oyaf330","type":"journal-article","created":{"date-parts":[[2025,10,4]],"date-time":"2025-10-04T11:50:16Z","timestamp":1759578616000},"source":"Crossref","is-referenced-by-count":0,"title":["Management of Canadian patients with refractory or relapsed diffuse large B-cell lymphoma in the real world: a subanalysis of the RE-MIND2 study"],"prefix":"10.1093","volume":"30","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2570-339X","authenticated-orcid":false,"given":"Anthea","family":"Peters","sequence":"first","affiliation":[{"name":"Department of Oncology, Cross Cancer Institute, University of Alberta , Edmonton, AB T6G 1Z2,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Grzegorz S","family":"Nowakowski","sequence":"additional","affiliation":[{"name":"Division of Hematology, Mayo Clinic , Rochester, MN 55905,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rosy","family":"Dabas","sequence":"additional","affiliation":[{"name":"Incyte Biosciences Canada Medical Affairs - Hematology\/Oncology, , Villle St Laurent, QC H4S 0A9,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Theresa","family":"Amoloja","sequence":"additional","affiliation":[{"name":"Incyte Corporation Global Epidemiology and RWE Statistics, , Wilmington, DE 19803,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhenyi","family":"Xue","sequence":"additional","affiliation":[{"name":"Incyte Corporation Global Epidemiology and RWE Statistics, , Wilmington, DE 19803,","place":["United States"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Caroline","family":"Koch","sequence":"additional","affiliation":[{"name":"Incyte Biosciences Canada Medical Affairs - Hematology\/Oncology, , Villle St Laurent, QC H4S 0A9,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eva E","family":"Waltl","sequence":"additional","affiliation":[{"name":"MorphoSys AG Global Medical Affairs, , Planegg 82152,","place":["Germany"]}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Isabelle","family":"Fleury","sequence":"additional","affiliation":[{"name":"H\u00f4pital Maisonneuve-Rosemont, Montreal University Hematology-Oncology and Cell Therapy University Institute, , Montreal, QC H1T 2M4,","place":["Canada"]}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"286","published-online":{"date-parts":[[2025,10,6]]},"reference":[{"key":"2025111120321334400_oyaf330-B1","doi-asserted-by":"publisher","first-page":"842","DOI":"10.1056\/NEJMra2027612","article-title":"Diffuse large B-cell lymphoma","volume":"384","author":"Sehn","year":"2021","journal-title":"N Engl J Med"},{"author":"National Comprehensive Cancer Network (NCCN)","key":"2025111120321334400_oyaf330-B2"},{"key":"2025111120321334400_oyaf330-B3","doi-asserted-by":"publisher","first-page":"V116","DOI":"10.1093\/annonc\/mdv304","article-title":"Diffuse large B-cell lymphoma (DLBCL): ESMO clinical practice guidelines for diagnosis, treatment and follow-up","volume":"26 Suppl 5","author":"Tilly","year":"2015","journal-title":"Ann Oncol"},{"key":"2025111120321334400_oyaf330-B4","doi-asserted-by":"publisher","first-page":"235","DOI":"10.1056\/NEJMoa011795","article-title":"CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma","volume":"346","author":"Coiffier","year":"2002","journal-title":"N Engl J Med"},{"key":"2025111120321334400_oyaf330-B5","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1016\/j.beha.2018.07.014","article-title":"Management of relapsed\/refractory DLBCL","volume":"31","author":"Sarkozy","year":"2018","journal-title":"Best Pract Res Clin Haematol"},{"key":"2025111120321334400_oyaf330-B6","doi-asserted-by":"publisher","first-page":"267","DOI":"10.1111\/bjh.18197","article-title":"Outcomes of relapsed\/refractory diffuse large B-cell lymphoma and influence of chimaeric antigen receptor T trial eligibility criteria in second line\u2013a population-based study of 736 patients","volume":"198","author":"Harrysson","year":"2022","journal-title":"Br J Haematol"},{"key":"2025111120321334400_oyaf330-B7","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.1007\/s00277-015-2467-z","article-title":"Outcome of patients with primary refractory diffuse large B cell lymphoma after R-CHOP treatment","volume":"94","author":"Hitz","year":"2015","journal-title":"Ann Hematol"},{"key":"2025111120321334400_oyaf330-B8","doi-asserted-by":"publisher","first-page":"2161","DOI":"10.1080\/10428194.2021.1901090","article-title":"Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory\/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation","volume":"62","author":"Cazelles","year":"2021","journal-title":"Leuk Lymphoma"},{"key":"2025111120321334400_oyaf330-B9","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1038\/bmt.2015.213","article-title":"Outcome of patients with relapsed diffuse large B-cell lymphoma who fail second-line salvage regimens in the international CORAL study","volume":"51","author":"Van Den Neste","year":"2016","journal-title":"Bone Marrow Transplant"},{"key":"2025111120321334400_oyaf330-B10","doi-asserted-by":"publisher","first-page":"1800","DOI":"10.1182\/blood-2017-03-769620","article-title":"Outcomes in refractory diffuse large B-cell lymphoma: results from the international SCHOLAR-1 study","volume":"130","author":"Crump","year":"2017","journal-title":"Blood"},{"author":"Gilead Sciences Canada I","key":"2025111120321334400_oyaf330-B11"},{"author":"Bristol-Myers Squibb Canada","key":"2025111120321334400_oyaf330-B12"},{"author":"Novartis Pharmaceuticals Canada Inc","key":"2025111120321334400_oyaf330-B13"},{"key":"2025111120321334400_oyaf330-B14","doi-asserted-by":"publisher","first-page":"e19002","DOI":"10.1200\/JCO.2024.42.16_suppl.e19002","article-title":"Real-world barriers to CAR-T access: a Canadian referral center perspective","volume":"42","author":"Shi","year":"2024","journal-title":"J Clin Oncol"},{"author":"Hoffmann-La Roche Limited","key":"2025111120321334400_oyaf330-B15"},{"author":"AbbVie Corporation","key":"2025111120321334400_oyaf330-B16"},{"author":"Hoffmann-La Roche Limited","key":"2025111120321334400_oyaf330-B17"},{"author":"Swedish Orphan Biovitrum AB","key":"2025111120321334400_oyaf330-B18"},{"key":"2025111120321334400_oyaf330-B19","doi-asserted-by":"publisher","first-page":"978","DOI":"10.1016\/S1470-2045(20)30225-4","article-title":"Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study","volume":"21","author":"Salles","year":"2020","journal-title":"Lancet Oncol"},{"author":"Incyte Corporation","key":"2025111120321334400_oyaf330-B20"},{"key":"2025111120321334400_oyaf330-B21","doi-asserted-by":"publisher","first-page":"553","DOI":"10.3324\/haematol.2023.283480","article-title":"Tafasitamab for patients with relapsed or refractory diffuse large B-cell lymphoma: final 5-year efficacy and safety findings in the phase II L-MIND study","volume":"109","author":"Duell","year":"2024","journal-title":"Haematologica"},{"key":"2025111120321334400_oyaf330-B22","doi-asserted-by":"publisher","first-page":"4003","DOI":"10.1158\/1078-0432.CCR-21-3648","article-title":"Improved efficacy of tafasitamab plus lenalidomide versus systemic therapies for relapsed\/refractory DLBCL: RE-MIND2, an observational retrospective matched cohort study","volume":"28","author":"Nowakowski","year":"2022","journal-title":"Clin Cancer Res"},{"key":"2025111120321334400_oyaf330-B23","doi-asserted-by":"publisher","first-page":"3059","DOI":"10.1200\/JCO.2013.54.8800","article-title":"Recommendations for initial evaluation, staging, and response assessment of Hodgkin and non-Hodgkin lymphoma: the Lugano classification","volume":"32","author":"Cheson","year":"2014","journal-title":"J Clin Oncol"},{"key":"2025111120321334400_oyaf330-B24","doi-asserted-by":"publisher","first-page":"579","DOI":"10.1200\/JCO.2006.09.2403","article-title":"Revised response criteria for malignant lymphoma","volume":"25","author":"Cheson","year":"2007","journal-title":"J Clin Oncol"},{"key":"2025111120321334400_oyaf330-B25","doi-asserted-by":"publisher","first-page":"1244","DOI":"10.1200\/JCO.1999.17.4.1244","article-title":"Report of an international workshop to standardize response criteria for non-Hodgkin\u2019s lymphomas","volume":"17","author":"Cheson","year":"1999","journal-title":"J Clin Oncol"},{"year":"2019","author":"National Comprehensive Cancer Network (NCCN)","key":"2025111120321334400_oyaf330-B26"},{"key":"2025111120321334400_oyaf330-B27","doi-asserted-by":"publisher","first-page":"29","DOI":"10.2307\/2530286","article-title":"A confidence interval for the median survival time","volume":"38","author":"Brookmeyer","year":"1982","journal-title":"Biometrics"},{"key":"2025111120321334400_oyaf330-B28","doi-asserted-by":"crossref","first-page":"173","DOI":"10.3390\/curroncol32030173","article-title":"Enhancing CAR-T efficacy in large B-cell lymphoma with radiation bridging therapy: a real-world single-center experience","volume":"32","author":"Laverdure","year":"2025","journal-title":"Curr Oncol"},{"key":"2025111120321334400_oyaf330-B29","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1016\/j.clml.2020.05.008","article-title":"Real world outcomes in patients with relapsed\/refractory diffuse large B-cell lymphoma receiving palliative intent therapies","volume":"20","author":"Ayers","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025111120321334400_oyaf330-B30","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1111\/bjh.14813","article-title":"Clinical heterogeneity of diffuse large B cell lymphoma following failure of front-line immunochemotherapy","volume":"179","author":"Farooq","year":"2017","journal-title":"Br J Haematol"},{"key":"2025111120321334400_oyaf330-B31","doi-asserted-by":"publisher","first-page":"4669","DOI":"10.1182\/bloodadvances.2020002118","article-title":"Outcomes in patients with DLBCL treated with commercial CAR T cells compared with alternate therapies","volume":"4","author":"Sermer","year":"2020","journal-title":"Blood Adv"},{"key":"2025111120321334400_oyaf330-B32","doi-asserted-by":"publisher","first-page":"6124","DOI":"10.1158\/1078-0432.CCR-21-1471","article-title":"RE-MIND: comparing tafasitamab + lenalidomide (L-MIND) with a real-world lenalidomide monotherapy cohort in relapsed or refractory diffuse large B-cell lymphoma","volume":"27","author":"Zinzani","year":"2021","journal-title":"Clin Cancer Res"},{"key":"2025111120321334400_oyaf330-B33","doi-asserted-by":"publisher","first-page":"2253","DOI":"10.1007\/s00277-020-04342-6","article-title":"Analysis of real-world data in patients with relapsed\/refractory diffuse large B cell lymphoma who received salvage chemotherapy in the rituximab era","volume":"100","author":"Fuji","year":"2021","journal-title":"Ann Hematol"},{"key":"2025111120321334400_oyaf330-B34","doi-asserted-by":"publisher","first-page":"161","DOI":"10.1002\/ajh.24615","article-title":"Diffuse large B-cell lymphoma with primary treatment failure: ultra-high risk features and benchmarking for experimental therapies","volume":"92","author":"Costa","year":"2017","journal-title":"Am J Hematol"},{"key":"2025111120321334400_oyaf330-B35","doi-asserted-by":"publisher","first-page":"e373","DOI":"10.1016\/j.clml.2020.11.008","article-title":"Outcomes of transplant-eligible patients with relapsed or refractory diffuse large B-cell lymphoma after second-line salvage chemotherapy: the Gustave Roussy experience","volume":"21","author":"Rassy","year":"2021","journal-title":"Clin Lymphoma Myeloma Leuk"},{"key":"2025111120321334400_oyaf330-B36","doi-asserted-by":"publisher","first-page":"591","DOI":"10.1111\/bjh.14453","article-title":"Outcomes of primary refractory diffuse large B-cell lymphoma (DLBCL) treated with salvage chemotherapy and intention to transplant in the rituximab era","volume":"176","author":"Vardhana","year":"2017","journal-title":"Br J Haematol"},{"key":"2025111120321334400_oyaf330-B37","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1016\/j.clml.2022.06.010","article-title":"Retrospective analysis of the efficacy and tolerability of gemcitabine-based chemotherapy in relapsed\/refractory lymphoma patients not eligible for stem cell transplant","volume":"22","author":"Chiu","year":"2022","journal-title":"Clin Lymphoma Myeloma Leuk"}],"container-title":["The Oncologist"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/oncolo\/advance-article-pdf\/doi\/10.1093\/oncolo\/oyaf330\/64521961\/oyaf330.pdf","content-type":"application\/pdf","content-version":"am","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/11\/oyaf330\/64521961\/oyaf330.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/oncolo\/article-pdf\/30\/11\/oyaf330\/64521961\/oyaf330.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T01:32:17Z","timestamp":1762911137000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/oncolo\/article\/doi\/10.1093\/oncolo\/oyaf330\/8276126"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,6]]},"references-count":37,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11,11]]}},"URL":"https:\/\/doi.org\/10.1093\/oncolo\/oyaf330","relation":{},"ISSN":["1083-7159","1549-490X"],"issn-type":[{"type":"print","value":"1083-7159"},{"type":"electronic","value":"1549-490X"}],"subject":[],"published-other":{"date-parts":[[2025,11]]},"published":{"date-parts":[[2025,10,6]]},"article-number":"oyaf330"}}